Latest Onyx Pharmaceuticals Stories
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Aug.
- Zalani joins Intarcia to drive the strategic and operational direction of Intarcia's Global Regulatory and Quality efforts with health authorities, partners and external stakeholders -
-- Nexavar is the only approved treatment for patients with RAI-refractory differentiated thyroid cancer -- Nexavar significantly extended progression-free survival
New Chief Medical Officer Brings Wealth of Experience in Innovative Therapies in Oncology SANTA MONICA, Calif., June 2, 2014 /PRNewswire/ -- Kite Pharma, Inc., a clinical-stage biopharmaceutical
SOUTH SAN FRANCISCO, May 6, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that the company's board of directors has elected Ted W.
WHIPPANY, N.J. and THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., April 23, 2014 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc.
SAN DIEGO, April 2, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc.
Top Tier Panelists from Onyx Pharmaceuticals, BioMarin Pharmaceutical, San Francisco State University, and Clinovo Share Experience on How to Conduct Successful Outsourcing Strategies
SAN DIEGO, March 24, 2014 /PRNewswire/ -- Seragon Pharmaceuticals Inc., a clinical-stage biotechnology company focused on the development of drugs for hormone-driven cancers, today announced